Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) CEO Amit Gupta sold 22,607 shares of Cardlytics stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total transaction of $87,036.95. Following the completion of the sale, the chief executive officer now owns 178,519 shares of the company’s stock, valued at $687,298.15. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Amit Gupta also recently made the following trade(s):
- On Wednesday, October 2nd, Amit Gupta sold 7,543 shares of Cardlytics stock. The shares were sold at an average price of $3.08, for a total transaction of $23,232.44.
Cardlytics Stock Up 2.6 %
Shares of CDLX stock opened at $3.88 on Friday. Cardlytics, Inc. has a 12 month low of $2.89 and a 12 month high of $20.52. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 1.01. The firm has a market cap of $189.28 million, a PE ratio of -0.88 and a beta of 1.67. The stock has a 50 day moving average of $3.61 and a 200-day moving average of $7.25.
Institutional Investors Weigh In On Cardlytics
Hedge funds have recently made changes to their positions in the stock. Canton Hathaway LLC raised its holdings in Cardlytics by 95.7% in the 2nd quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock valued at $37,000 after acquiring an additional 2,200 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Cardlytics during the 3rd quarter worth approximately $45,000. Creative Planning increased its position in shares of Cardlytics by 35.4% during the third quarter. Creative Planning now owns 29,537 shares of the company’s stock valued at $95,000 after purchasing an additional 7,721 shares during the period. XTX Topco Ltd acquired a new position in shares of Cardlytics in the second quarter valued at $107,000. Finally, Quest Partners LLC lifted its position in Cardlytics by 160.4% in the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock worth $147,000 after purchasing an additional 11,061 shares during the period. Institutional investors own 68.10% of the company’s stock.
Analyst Ratings Changes
CDLX has been the topic of several analyst reports. Northland Capmk downgraded shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Evercore ISI began coverage on Cardlytics in a report on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective on the stock. Needham & Company LLC lowered Cardlytics from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. Lake Street Capital downgraded Cardlytics from a “buy” rating to a “hold” rating and lowered their price target for the company from $18.00 to $5.00 in a report on Thursday, August 8th. Finally, Bank of America cut shares of Cardlytics from a “neutral” rating to an “underperform” rating and reduced their price objective for the stock from $4.00 to $3.50 in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the stock. According to data from MarketBeat, Cardlytics currently has a consensus rating of “Hold” and a consensus target price of $6.92.
Get Our Latest Analysis on CDLX
About Cardlytics
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Further Reading
- Five stocks we like better than Cardlytics
- What is Forex and How Does it Work?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- How to Invest in Blue Chip Stocks
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.